MedTrace Logo

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

NCT05722405 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-05

No results posted yet for this study

Summary

Ixazomib combined with low-dose lenalidomide(10mg) vs Ixazomib alone as maintenance regimen in patients with high-risk multiple myeloma after induction and consolidation of VRD-based regimen.

Conditions

Interventions

DRUG

Ixazomib plus low-dose lenalidomide

Whether Ixazomib combined with low-dose lenalidomide improves the outcome and prognosis of patients with high-risk multiple myeloma as a maintenance treatment option compared to ixazolomib alone

DRUG

Ixazomib

Ixazomib alone

Sponsors & Collaborators

  • Affiliated Hospital of Jiaxing University

    collaborator OTHER

  • Huzhou Central Hospital

    collaborator OTHER

  • Lishui Country People's Hospital

    collaborator OTHER

  • Dongyang People's Hospital

    collaborator OTHER

  • Shangyu People's Hospital

    collaborator OTHER

  • Shaoxing People's Hospital

    collaborator OTHER

  • Shaoxing Second Hospital

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Yang Xu, Dr. · Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2026-06-30
Completion
2028-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05722405 on ClinicalTrials.gov